Sodium-dependent noradrenaline transporter (NET) and alpha-1A, alpha-1B, alpha-1D, and alpha-2C adrenergic receptors (NET/ADRA1/ADRA2C)

The noradrenergic system target complex, comprising the norepinephrine transporter (NET) and the alpha-1 (α1A, α1B, α1D) and alpha-2C (α2C) adrenergic receptors, is a multi-protein ensemble central to sympathetic and central nervous system signaling. NET (SLC6A2) is a monoamine transporter that terminates the action of norepinephrine by facilitating its reuptake into presynaptic terminals [1]. The alpha-1 adrenergic receptors are Gq-coupled receptors that mediate excitatory effects, including smooth muscle contraction in the vasculature and prostate [2]. The alpha-2C receptor is a Gi-coupled subtype that functions as a presynaptic autoreceptor, inhibiting further neurotransmitter release and modulating cognitive processes such as the startle response [3]. This specific pharmacological profile is targeted by various classes of drugs, including tricyclic antidepressants (TCAs) and certain atypical antipsychotics, to treat conditions like major depressive disorder, ADHD, and benign prostatic hyperplasia [4][5]. While effective, simultaneous modulation of these targets often results in side effects such as orthostatic hypotension and tachycardia due to the disruption of autonomic homeostasis [6].

Other names

SLC6A2ADRA1AADRA1BADRA1DADRA2CAlpha-1 adrenoceptorsAlpha-2C adrenoceptorNoradrenaline transporterNET

Inhibition of the norepinephrine transporter (NET) to increase synaptic norepinephrine levels, combined with the antagonism of alpha-1 (α1A, α1B, α1D) and alpha-2C adrenergic receptors to modulate smooth muscle tone and presynaptic feedback loops.